NBT-508

N/A

Report date: 2022/05/07 10:55:32

Base Information

Drug NameNBT-508
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD79B
TargetsB-cell antigen receptor complex-associated protein beta chain
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNewbio Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesXingang (Shanghai) Biomedical Technology Co LtdTot Biopharm Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A